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Abstract
Background: Comfrey is consumed by humans as a vegetable and a tea, and has been used as an herbal medicine
for more than 2000 years. Comfrey, however, is hepatotoxic in livestock and humans and carcinogenic in
experimental animals. Our previous study suggested that comfrey induces liver tumors by a genotoxic mechanism
and that the pyrrolizidine alkaloids in the plant are responsible for mutation induction and tumor initiation in rat
liver.
Results: In this study, we identified comfrey-induced gene expression profile in the livers of rats. Groups of 6
male transgenic Big Blue rats were fed a basal diet and a diet containing 8% comfrey roots, a dose that resulted
in liver tumors in a previous carcinogenicity bioassay. The animals were treated for 12 weeks and sacrificed one
day after the final treatment. We used a rat microarray containing 26,857 genes to perform genome-wide gene
expression studies. Dietary comfrey resulted in marked changes in liver gene expression, as well as in significant
decreases in the body weight and increases in liver mutant frequency. When a two-fold cutoff value and a P-value
less than 0.01 were selected, 2,726 genes were identified as differentially expressed in comfrey-fed rats compared
to control animals. Among these genes, there were 1,617 genes associated by Ingenuity Pathway Analysis with
particular functions, and the differentially expressed genes in comfrey-fed rat livers were involved in metabolism,
injury of endothelial cells, and liver injury and abnormalities, including liver fibrosis and cancer development.
Conclusion: The gene expression profile provides us a better understanding of underlying mechanisms for
comfrey-induced hepatic toxicity. Integration of gene expression changes with known pathological changes can be
used to formulate a mechanistic scheme for comfrey-induced liver toxicity and tumorigenesis.
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Background
Comfrey belongs to the family Boraginaceae. Three plant
species in the genus Symphytum  contribute to the crop
known as comfrey, Symphytum officinale L. (wild or com-
mon comfrey; the major comfrey species), S. asperum Lep-
echin (prickly or rough comfrey), and S. x uplandicum
Nyman (quaker, Russian, or blue comfrey; a natural
hybrid of S. officinale L. and S. asperum Lepechin). Symphy-
tum officinale L. is a tall perennial with large hairy leaves
and small purple flowers [1]. Comfrey has been used as an
herbal medicine for more than two thousand years for the
treatment of broken bones, tendon damage, ulcerations in
the gastrointestinal tract, and lung congestion, as well as
for wound healing and/or reducing joint inflammation
when it is applied externally [2].
In addition to essential nutrients, comfrey also contains
pyrrolizidine alkaloids (PAs). PAs are constituents of over
6000 plants, and many of them are hepatotoxic and carci-
nogenic in humans and animals [3]. In the liver, PAs are
transformed to pyrroles by the mixed-function oxidases.
Pyrroles exert their toxic effect by reacting with cellular
macromolecules, including proteins and DNA [4]. There-
fore, comfrey's therapeutic use might increase the risk of
liver toxicity. Many countries including Canada, Ger-
many, and the UK, have restricted its availability. In 2001,
the US Food and Drug Administration requested volun-
tary compliance for the removal of products containing
comfrey [5].
The major hepatotoxic manifestation in humans ingesting
comfrey is the hepatic veno-occlusive lesion (VOD) [6,7],
also called sinusoidal obstruction syndrome (SOS) [8].
Comfrey is also carcinogenic in rats, which suggests the
potential tumorigenic effects of the plant [9]. Hepatocel-
lular adenomas were induced in rats receiving a diet con-
taining comfrey. Feeding rats comfrey leaves produced a
dose-dependent reduction in survival and an increase in
liver tumor incidence [9]. Comfrey roots are much more
toxic than the leaves.
In a previous study, we developed evidence indicating that
the liver tumors induced by feeding rats 2% comfrey root
were generated by a genotoxic mechanism and that the
PAs in the plant were responsible for mutation induction
and tumor initiation in rat liver [10]. Considering the fact
that rats tolerate diets containing up to 33% comfrey
leaves and 8% comfrey roots for relatively long periods of
time (at least 6 months) [9], in the present study, we eval-
uated the mutagenicity of 8% comfrey root. Using a toxi-
cogenomic approach, we analyzed the changes in global
gene expressions in the liver of rats following comfrey-
treatment.
Results
Growth curve of rats fed with 8% comfrey root
Male Big Blue transgenic rats were fed with 8% comfrey
root for 12 weeks. The mean body weight of the comfrey-
fed rats was less than that of the vehicle controls through-
out the study (Figure 1). Rats fed with comfrey weighed
5%, 23%, and 35% less than the control rats after 1, 6, and
12 weeks of the study, respectively, and displayed little
weight gain after 6 weeks of feeding with comfrey.
Mutant frequency (MF) in the liver cII gene of comfrey-fed 
rats
The results of cII MF analyses in the comfrey-fed and con-
trol rats are shown in Figure 2. DNA from each liver was
packaged 2–4 times either to confirm the MF or to obtain
a minimum of 2 × 105 plaque-forming units for mutant
detection. The MF for rats fed with 8% comfrey was 139 ±
35 (SD) × 10-6, which was similar to the MF previously
detected in 2% comfrey-fed rats [10] and significantly
increased over the control group (30 ± 16 × 10-6, P <
0.001).
Mutation spectrum in the liver cII gene from comfrey-fed 
rats
Comfrey-induced mutations in the liver cII  gene were
evaluated by DNA sequence analysis of 106 mutants iso-
lated from 6 rats fed a diet containing 8% comfrey root.
Since mutations that were found more than once among
the mutants isolated from a single animal were assumed
to be siblings and to represent only one independent
mutation, a total of 99 independent mutations were iden-
tified. Table 1 summarizes the types of cII  mutations
observed in the livers of rats fed 8% comfrey compared
Mean body weight of Big Blue rats fed with 8% comfrey root  for 12 weeks Figure 1
Mean body weight of Big Blue rats fed with 8% 
comfrey root for 12 weeks. The data represent the 
means ± SD of 6 rats from the control (■) and the 8% 
comfrey root (●) groups.
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with mutation spectra of control and 2% comfrey-fed rats
that we reported previously [10]. The overall pattern of
mutations in 8% comfrey-fed rats differed significantly
from controls (P < 0.0001), but did not differ from 2%
comfrey-fed rats. Among the independent mutations,
about 85% from both the comfrey-treated and control rats
were base pair substitutions. G:C → T:A transversion
(41%) was the major type of mutation in the 8% comfrey-
fed rats, whereas G:C → A:T transition was the predomi-
nant mutation in the controls. In addition, a 13% fre-
quency of tandem base substitutions was observed among
the mutations from the 8% comfrey-fed rats. The 8%
comfrey-fed rats had more large deletions than control
rats, although the percentages of frameshift mutations
were the same.
Gene expression regulated by comfrey-treatment
In order to determine gene expression changes associated
with comfrey exposure, we employed the Genome Survey
Microarray, which contains 26,857 verified rat genes. We
isolated total RNA from the livers of 6 control and 6
comfrey-fed rats. For the purpose of visualizing the data,
the intensities of the whole rat gene data were analyzed by
Principal Components Analysis within ArrayTrack (Figure
3). It demonstrates that one array of sample 6 from the
control group appears to be quite different from the rest
of the arrays, which was further identified as an outlier
array by the Pearson's correlation coefficient of pair-wise
log2 intensity correlation (data not shown). This outlier
was excluded from further data analysis. A separation
between control and comfrey-treated groups was clearly
observed, suggesting that there was a clear comfrey-treat-
ment effect on liver gene expression (Figure 3). To select
significant genes, minimum requirements were estab-
lished for both a two-fold change in the gene expression
compared to the controls and a P-value less than 0.01 for
the difference. A total of 2,726 genes satisfied the require-
ments; 1,235 genes were up-regulated and 1,491 genes
were down-regulated in response to comfrey treatment
(Figure 4). Among the regulated genes, 1,671 were identi-
fied by Ingenuity Pathway Analysis. In this study, we
focused on genes involved in metabolism, injury of
endothelial cells, and liver injury and abnormalities.
Genes associated with drug metabolizing genes
Since the PAs in comfrey require metabolic activation to
exert their biological effects, we investigated the gene
expression changes of drug metabolizing genes. We
observed the up- or down-regulation of many cytochrome
P450 genes (e.g., Cyp2c12, Cyp3a18, Cyp4a12, Cyp26),
glutathione  S-transferases (Gsta3, Gstm3, and Gstp1),
ATP-binding cassette transporters (e.g., Abcb9 and
Abcc3), and other metabolism-associated genes, includ-
Table 1: Summary of independent mutations in the liver cII gene from comfrey-fed and control Big Blue rats
Type of mutation Control * 8% comfrey • 2% comfrey •, *
Number % Number % Number %
G:C → C:G 5 11 6 6 11 6
G:C → A:T 20 43 11 11 24 12
G:C → T:A 9 20 40 41 83 42
A:T → T:A 1 2 4 4 5 2
A:T → G:C 1 2 6 6 9 4
A:T → C : G 3744 7 3
Frameshift 7 15 14 14 26 13
Complex 0 0 1 1 2 1
Tandem-base substitution 0 0 13 13 33 17
Total mutants screened 46 100 99 100 200 100
•Spectra for 2% and 8% comfrey-fed rats were significantly different from the controls (P < 0.001). There was no significant difference between the 
spectra for 2% and 8% comfrey.
*Data are from literature [10].
Liver cII mutant frequencies in control and 8% comfrey-fed  rats Figure 2
Liver cII mutant frequencies in control and 8% 
comfrey-fed rats. The data represent the means ± SD 
from groups of 6 rats. *Significantly differed from control 
group (P < 0.001).BMC Bioinformatics 2006, 7(Suppl 2):S16
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ing NAD(P)H oxidoreductase (Nqo1) and aldehyde dehy-
drogenase (Aldh1a1). Table 2 shows the significant
changes in gene expression related to phase I, II, and III
drug metabolizing genes.
Genes involved in injury of endothelial cells
Considering the involvement of sinusoidal endothelial
cells and sometimes hepatic venular endothelial cells in
VOD/SOS [8], we focused on genes expressed in endothe-
Principal component analysis for gene expression profiles from livers of control and 8% comfrey-fed rats Figure 3
Principal component analysis for gene expression profiles from livers of control and 8% comfrey-fed rats. No 
specific cut off was applied and the intensity of whole rat genome data was used. The red and blue dots indicate control and 
comfrey-treated samples, respectively.
Figure 3. 
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lial cells. Table 3 summarizes the alteration of genes
related to cell death, apoptosis, and cell growth of
endothelial cells. For example, we observed the up-regula-
tion of previously reported tumor necrosis factors
(Tnfsf10, Tnfrsf6, and Tnfrsf12a), transforming growth
factor (Tgfb1 and Tgfb2), and other genes (such as,
Mmp2, PAI-1 or Serpine1, Plaur, Col4a2, and Edn1)
[8,11,12]. Several novel genes were responsive to comfrey
treatment, including activating transcription factor 3
(Atf3), B-cell cLL/lymphoma 2 (Bcl2), caspase 1 (Casp1),
mitogen-activated protein kinase 9 (Mapk9), and secreted
phosphoprotein 1 (Spp1).
Volcano plots (log2 fold change vs. -log2 P-value) Figure 4
Volcano plots (log2 fold change vs. -log2 P-value). A gene was identified as significantly changed if the fold change was 
greater than 2 (up or down) and the P-value was less than 0.01 in comparison to the control group. Each group consisted of 5–
6 replicates.BMC Bioinformatics 2006, 7(Suppl 2):S16
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Genes involved in liver injury and abnormalities
Endothelial damage can lead to hepatocellular injury, and
fibrotic reaction in the sinusoids is characterized as the
later stages of VOD/SOS. Chronic comfrey treatment also
resulted in the induction of a number of genes involved in
liver injury and abnormalities. Significantly changed
genes were divided into subsets based on functionality,
and categories included cell death, growth, fibrosis, mor-
phology, and liver cancer development (Table 4). Sixteen
genes were functionally categorized in liver cell death.
Besides the tumor necrosis factors and transforming
growth factor, comfrey treatment resulted in strong up-
regulation of cyclin-dependent kinase inhibitor 1A
(Cdkn1a) and heme oxyenase 1 (Hmox1), as well as
down-regulation of epidermal growth factor (Egf) and
CCAAT/enhancer binding protein beta (Cebpb). Of note,
genes involved in cell growth were up-regulated along
with the genes involved in liver cell death, such as cyclin
E1 (Ccne1), hepatocyte growth factor (Hgf), and tissue
inhibitor of metalloproteinase 1 (Timp1).
Liver fibrosis is the hallmark of all chronic liver diseases,
irrespective of their origin. Ingenuity Pathway Analysis
showed that sixteen significantly regulated genes
appeared to have a role in liver fibrosis (Table 4). Most of
them encode cytokines (Hgf, Igf1, Lif, Tgfb1, and Tnfrsf6),
angiogenic molecules (Agt, and Agtr1a), chemokines and
their receptors (Ccr2, Cxcl4, and Cxcl12), coagulation cas-
cade genes (PAI-1/Serpine1 and F11), and cytoskeletal
molecules (Krt2-8). Moreover, eight genes related to the
development of liver cancer were among the most dis-
criminating genes involved in cancer development, such
as growth arrest and DNA damage inducible 45 alpha
(Gadd45a), B-cell cLL/lymphoma 2 (Bcl2), N-myc down-
stream regulated 1 (Ndr1), and xeroderma pigmentosum
complementation group C (Xpc).
Discussion
Comfrey was one of the most popular herbal teas in the
world, including the United States. Although its popular-
ity has declined due to the understanding of its dangers, it
is still available commercially in several forms. The regular
use of comfrey is a potential health risk owing to the pres-
ence of PAs. Comfrey contains as many as nine PAs,
including acetyl intermedine, acetyl lycopsamine, echimi-
dine, intermedine, lasiocarpine, lycopsamine, symland-
ine, symphytine, and symviridine [13-15]. The PA content
of comfrey is less than 1% and depends on the plant part
Table 2: Genes involved in drug metabolism altered by comfrey treatment in liver
Gene symbol Gene description Locus link ID Fold change P-value
Phase I metabolism
Cyp2c cytochrome P450, family 2, subfamily c 29277 0.03 0.00000
Cyp2c12 cytochrome P450, family 2, subfamily c 25011 6.52 0.00000
Cyp2c39 cytochrome P450, family 2, subfamily c 29298 0.35 0.00001
Cyp2d1 cytochrome P450, family 2, subfamily d 266684 0.38 0.00000
Cyp2d2 cytochrome P450, family 2, subfamily d 25053 0.43 0.00002
Cyp2d3 cytochrome P450, family 2, subfamily d 24303 0.39 0.00000
Cyp2d5 cytochrome P450, family 2, subfamily d 286963 0.44 0.00000
Cyp3a18 cytochrome P450, family 3, subfamily a 252931 0.38 0.00060
Cyp4a3 cytochrome P450, family 4, subfamily a 298423 0.46 0.00010
Cyp4a12 cytochrome P450, family 4, subfamily a 266674 0.36 0.00015
Cyp4b1 cytochrome P450, family 4, subfamily b 24307 0.32 0.00008
Cyp4f5 cytochrome P450, family 4, subfamily f 286905 4.71 0.00000
Cyp4f14 cytochrome P450, family 4, subfamily f 56266 0.48 0.00005
Cyp4f18 cytochrome P450, family 4, subfamily f 72054 0.47 0.00014
Cyp7a1 cytochrome P450, family 7, subfamily a 25428 6.16 0.00067
Cyp7b1 cytochrome P450, family 7, subfamily b 13123 2.15 0.00169
Cyp11b3 cytochrome P450, family 11, subfamily b 353498 0.43 0.00032
Cyp26 cytochrome P450, family 26 154985 18.54 0.00005
Cyp39a1 cytochrome P450, family 39, subfamily a 56050 0.29 0.00315
Phase II metabolism
Gsta3 glutathione S-transferase, alpha 3 14859 14.47 0.00001
Gstm3 glutathione S-transferase, mu 3 81869 0.39 0.00173
Gstp1 glutathione S-transferase, pi 1 14869 3.16 0.00001
Phase III metabolism
Abcb9 ATP-binging cassette, subfamily b (MDR/TAP) 63886 0.23 0.00292
Abcc1 ATP-binging cassette, subfamily c (CFTR/MRP) 24565 2.65 0.00132
Abcc3 ATP-binging cassette, subfamily c (CFTR/MRP) 140668 21.20 0.00006
Abcc6 ATP-binging cassette, subfamily c (CFTR/MRP) 81642 0.42 0.00000
Abcc8 ATP-binging cassette, subfamily c (CFTR/MRP) 25559 0.10 0.00000BMC Bioinformatics 2006, 7(Suppl 2):S16
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Table 3: Genes involved in endothelial cells altered by comfrey treatment in liver
Gene symbol Gene description Locus link ID Fold change P-value
Cell death and apoptosis
*, • Angpt2 angiopoietin 2 11601 3.45 0.00121
App amyloid beta (A4) precursor protein 54226 4.69 0.00000
Atf3 activating transcription factor 3 25389 6.22 0.00010
Bcl2 B-cell cLL/lymphoma 2 24224 2.41 0.00500
Bcl2a1 Bcl2-related protein A1 170929 3.43 0.00022
Bcl2l Bcl2-like 12048 2.53 0.00000
Casp1 caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, convertase) 25166 2.26 0.00551
Cnp 2',3'-cyclic nucleotide 3' phosphodiesterase 1267 2.37 0.00010
• Col4a2 collagen, type IV, alpha 2 1284 2.81 0.00000
• Cxcr4 chemokine receptor (LCR1) 60628 3.22 0.00186
Dusp6 dual specificity phosphatase 6 116663 2.31 0.00036
Edn1 endothelin 1 24323 4.87 0.00033
Fgf1 fibroblast growth factor 1 25317 2.05 0.00057
*Gpr9 G protein-coupled receptor 9 (Cxcr3) 84475 2.02 0.00944
• Hgf hepatocyte growth factor 24446 3.18 0.00065
Hmox1 heme oxygenase 1 24451 3.23 0.00064
Il2 interleukin 2 116562 0.29 0.00010
Ins1 insulin 1 24505 0.22 0.00000
Lrp5 low density lipoprotein receptor-related protein 5 16973 0.35 0.00010
Mapk9 mitogen-activated protein kinase 9 50658 0.49 0.00009
Pparg peroxisome proliferator activated receptor, gamma 25664 0.32 0.00033
Serpinf1 serine (or cysteine) proteinase inhibitor, clade F), member 1 287526 0.49 0.00009
*Spp1 secreted phosphoprotein 1 25353 11.63 0.00003
*, • Tgfb1 transforming growth factor, beta 1 59086 2.11 0.00002
Tnfrsf6 tumor necrosis factor receptor superfamily, member 6 246097 3.40 0.00007
Tnfsf10 tumor necrosis factor (ligand) superfamily, member 10 246775 2.19 0.00366
Adhesion
Anxa1 annexin 1 25380 2.50 0.00009
Anxa5 annexin 5 25673 4.29 0.00000
Cd44 CD44 antigen 25406 2.65 0.00004
Cx3cl1 chemokine (C-X3-C motif) ligand 1 89808 2.55 0.00333
• Cxcl4 chemokine (C-X-C motif) ligand 4 56744 3.12 0.00008
Cyr61 cysteine rich protein 61 83476 4.54 0.00000
•Itga4 integrin alpha 4 16401 5.28 0.00002
•Itgav integrin alpha V 16410 2.00 0.00113
Selplg selectin P ligand 6404 2.26 0.00088
Cell movement
Agt angiotensinogen 24179 0.36 0.00000
Ccl2 chemokine (C-C motif) ligand 2 24770 4.27 0.00026
Cd151 CD151 antigen 64315 2.13 0.00000
Cd9 CD9 antigen 12527 2.10 0.00127
Ceacam1 carcinoembryonic antigen-related cell adhesion molecule 1 81613 0.49 0.00138
Cxcl12 chemokine (C-X-C motif) ligand 12 24772 0.19 0.00000
Edil3 EGF-like repeats and discoidin I-like domains 3 10085 3.57 0.00015
Efnb2 ephrin B2 13642 0.49 0.00006
Fgfr1 Fibroblast growth factor receptor 1 79114 2.25 0.00002
Id1 Inhibitor of DNA binding 1, helix-loop-helix protein (splice variation) 25261 2.89 0.00068
Lgals3 lectin, galactose binding, soluble 3 83781 2.31 0.00003
Mmp2 matrix metalloproteinase 2 17390 4.31 0.00000
Plaur urokinase plasminogen activator receptor 50692 2.93 0.00164
Ptk2b protein tyrosine kinase 2 beta 50646 3.85 0.00000
S100a4 S100 calcium-binding protein A4 24615 3.61 0.00001
Serpine1 serine (or cysteine) proteinase inhibitor, clade E, member 1 (plasminogen activator 
inhibitor type 1)
24617 30.94 0.00003
Stc1 stanniocalcin 1 81801 3.50 0.00306
TEK TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and 
mucosal)
7010 0.34 0.00012
Tgfb2 transforming growth factor, beta 2 81809 2.31 0.00458
Tnfrsf12a tumor necrosis factor receptor superfamily, member 12a 302965 2.91 0.00090
Genes also involved in adhesion* and cell movement• of endothelial cells.BMC Bioinformatics 2006, 7(Suppl 2):S16
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[15]. Higher PA concentrations occur in the roots of
comfrey than in the leaves, and commercially available
comfrey tablets containing high levels of PAs are likely to
be derived from comfrey roots [16,17]. PAs are the leading
plant toxins associated with disease in humans and ani-
mals.
Table 4: Genes involved in liver injury and abnormalities altered by comfrey-treatment
Gene symbol Gene description Locus link ID Fold change P-value
Cell death of liver cells
Bcl2 B-cell cLL/lymphoma 2 24224 2.41 0.00500
Bcl2l Bcl2-like 12048 2.53 0.00000
*Ccr2 chemokine receptor CCR2 gene 60463 2.47 0.00591
Cdkn1a cyclin-dependent kinase inhibitor 1A (p21) 114851 4.83 0.00014
Cebpb CCAAT/enhancer binding protein (C/EBP), beta 24253 0.46 0.00000
Egf epidermal growth factor 25313 0.36 0.00000
Hmox1 heme oxygenase 1 24451 3.23 0.00064
Ier3 immediate early response 3 294235 2.24 0.00002
Itgav integrin alpha V 16410 2.00 0.00113
*Krt2-8 keratin complex 2, basic, gene 8 25626 2.82 0.00000
Nos2 nitric oxide synthase 2, inducible 24599 3.38 0.00491
*, • Tgfb1 transforming growth factor, beta 1 59086 2.11 0.00002
Tnfrsf5 tumor necrosis factor receptor superfamily, member 5 21939 3.58 0.00009
*, • Tnfrsf6 Tumor necrosis factor receptor superfamily, member 6 246097 3.40 0.00007
Tnfsf10 tumor necrosis factor (ligand) superfamily, member 10 246775 2.19 0.00366
Ugcg UDP-glucose ceramide glycosyltransferase 83626 2.08 0.00000
Growth of liver cells
Ccne1 cyclin E1 898 7.93 0.00000
Edn1 endothelin 1 24323 4.87 0.00033
*, • Hgf hepatocyte growth factor 24446 3.18 0.00065
Inhba inhibin beta-A (activin A) 29200 0.08 0.00000
Tgfb1 transforming growth factor, beta 1 59086 2.11 0.00002
Timp1 tissue inhibitor of metalloproteinase 1 116510 4.25 0.00000
Liver fibrosis
Adrb2 adrenergic receptor, beta 2 24176 3.58 0.00000
Agt angiotensinogen 24179 0.36 0.00000
Agtr1a angiotensin II receptor, type 1 (AT1A) 24180 0.38 0.00000
Atf3 activating transcription factor 3 25389 6.22 0.00010
Cav caveolin 25404 3.15 0.00006
Cxcl4 chemokine (C-X-C motif) ligand 4 56744 3.12 0.00008
Cxcl12 chemokine (C-X-C motif) ligand 12 24772 0.19 0.00000
F11 coagulation factor XI 109821 0.43 0.00000
Igf1 insulin-like growth factor 1 24482 0.48 0.00000
Lif leukemia inhibitory factor 60584 0.41 0.00215
Serpine1 serine (or cysteine) proteinase inhibitor, clade E member 1 (plasminogen activator 
inhibitor type 1)
24617 30.94 0.00003
Liver morphology
Ccnd1 cyclin D1 58919 5.65 0.00002
Ins1 insulin 1 24505 0.22 0.00000
Junb Jun-B oncogene 24517 3.77 0.00001
Liver cancer development
Bcl2 B-cell cLL/lymphoma 2 24224 2.41 0.00500
Ccne1 cyclin E1 898 7.93 0.00000
Gadd45a growth arrest and DNA-damage-inducible 45 alpha 25112 2.15 0.00326
Gjb1 gap junction membrane channel protein beta 1 29584 0.48 0.00003
Hgf hepatocyte growth factor 24446 3.18 0.00065
Ndr1 N-myc downstream regulated 1 (Ndrg1) 10397 2.26 0.00020
Timp1 tissue inhibitor of metalloproteinase 1 116510 4.25 0.00000
Xpc xeroderma pigmentosum, complementation group C 7508 0.42 0.00001
*Five genes also involved in liver fibrosis and • three genes also involved in liver morphology.BMC Bioinformatics 2006, 7(Suppl 2):S16
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Several cases of VOD/SOS associated with comfrey inges-
tion have been reported in humans [6,7,18-20], as well as
in experimental animals [21]. Deleve and her colleagues
[22] have developed a reproducible animal model of
hepatic VOD, in which the rats are gavaged with a single
dose of PA, monocrotaline. The model exhibits the char-
acteristic clinical and histological features of hepatic VOD,
including the earliest manifestations (progressive injury
to the sinusoidal endothelial cells and central vein
endothelium), early VOD (centrilobular coagulative
necrosis and severe sinusoidal injury, hemorrhage, and
central vein endothelial damage), and late VOD (fibrotic
occulusion of the central veins) [22]. Comfrey and the
specific alkaloids in comfrey (e.g., symphytine and lasio-
carpine) induce hepatoadenoma and hemangioendothe-
lial sarcomas in rats [9,23,24]. The mechanisms by which
toxicity and carcinogenicity are produced are still not fully
understood. Gene expression profiling offers a powerful
approach for identifying differentially expressed genes
and identifying mechanisms.
Gene expression was markedly affected (Figure 3) in the
livers of rats exposed to 8% comfrey root, a dose that
resulted in significant decreases in body weight (Figure 1)
and increases in liver MF (Figure 2). Out of 26,857 genes
evaluated, the expression of 4,132 (15%) and 9,937
(37%) genes were altered more than 2-fold and 1.5-fold,
respectively. At P-values of 0.01 and 0.05, 7,518 (28% of
expressed genes) and 1,0341 (39%) genes, respectively,
displayed a significant effect after comfrey-treatment com-
pared to control group. In this study, differential gene
expression was considered significant for genes showing
at least a 2-fold up- or down-change, and a P < 0.01. In
total, 2,726 genes (10%) satisfied the requirements and
about half of them were down-regulated and half up-reg-
ulated in response to comfrey exposure (Figure 4). Such a
large number of significantly altered genes may partly
reflect the therapeutic effects of comfrey exerted through
plant components other than PAs [15]. In the present
study, we concentrated on the analysis of genes involved
in metabolism, injury of endothelial cells, and liver injury
and abnormalities.
Liver is the major organ for biotransformation of xenobi-
otics and drugs. PAs are metabolically activated to toxic,
alkylating pyrroles by mixed-function oxidases. The cyto-
chrome P450 (Cyp) superfamily contains 57 genes and
plays a critical role in the phase I metabolism of a variety
of xenobiotics including drugs, carcinogens, steroids and
eicosanoids [25]. In the present study, comfrey exposure
resulted in changes in the expression of 19 Cyp genes
(Table 2). Among phase I, II, and III drug metabolizing
genes, Cyp2c12, Cyp7a1, Cyp26, Gsta3, and Abcc3 were
increased 6-21-fold. In contrast, Cyp2c, Cyp39a1, Gstm3,
Abcc8, and others were reduced in the comfrey-treated liv-
ers. It is known that many herbal/dietary constituents
form reactive intermediates capable of irreversibly inhib-
iting various Cyps (reviewed in [25]). The resultant
metabolites lead to Cyp inactivation by chemical modifi-
cation of the heme, the apoprotein, or both, as a result of
covalent binding of modified heme to the apoprotein.
Phase II consists of conjugating enzymes, such as glutath-
ione S-transferases (GSTs), UDP-glucuronosyltransferases
(UGTs), and sulfatases. GSTs also participate in oxidative
stress release pathways. The altered expression of phase I
and phase II enzymes along with altered drug transport
proteins (phase III) could contribute to the increased sus-
ceptibility of rats to carcinogenic chemicals, such as
comfrey.
Sinusoidal endothelial cells are more susceptible than
hepatocytes to PAs that cause VOD/SOS [22]. Functional
annotation extracted from Ingenuity Pathway Analysis
revealed that many of the transcriptional responses were
associated with the apoptosis, cell death, adhesion, and
cell movement of endothelial cells (Table 3). The genes in
these pathways were highly expressed in comfrey-treated
livers; these genes included the endothelial cell markers
plasminogen activator inhibitor type 1 (PAI-1, also
known as Serpine1 and Serpine2) and tissue plasminogen
activator (Plat), and the cytokine tumor necrosis factors
(Tnfrsf6, Tnfrsf12a, and Tnfsf10), and transforming
growth factors (Tgfb1 and Tgfb2). Induction of a number
of genes involved in the injury of endothelial cells was
also detected, including endothelin 1 (Edn1), urokinase
plasminogen activator receptor (Plaur), collagen type IV
alpha 2 (Col4a2), matrix metalloproteinase 2 (Mmp2),
mitogen-activated protein kinase 9 (Mapk9), and secreted
phosphoprotein 1 (Spp1). It has been reported that Edn1
is a mediator of hepatic sinusoidal constriction, and
increased activity of matrix metalloproteinases is respon-
sible for changes of sinusoidal endothelial cells [11]. Ele-
vated plasma PAI-1 levels are useful in distinguishing
VOD/SOS [26]. Endothelial injury is the initiating event
in the cascade of events leading to the hepatic changes and
clinical manifestation of VOD/SOS [27]. Our results offer
a more comprehensive overview of the molecular
responses to comfrey exposure by expression of multiple
genes in liver endothelial cells.
PAs in comfrey can reach the hepatocytes via the sinusoi-
dal blood, and their toxic metabolites lead to immediate
damage to the hepatocytes [4]. Genes involved in liver cell
death and growth were also induced or repressed in
response to comfrey treatment (Table 4), including tumor
necrosis factors, transforming growth factor β, chemokine
receptor CCR2 gene (Ccr2), heme oxygenase 1 (Hmox1),
immediate early response 3 (Ier3), cyclin-dependent
kinase inhibitor (Cdkn1a), inhibin beta A (Inhba), and
tissue inhibitor of metalloproteinase 1 (Timp1). It is wellBMC Bioinformatics 2006, 7(Suppl 2):S16
Page 10 of 15
(page number not for citation purposes)
known that Hmox1 induction is a protective mechanism
against the oxidative stress associated with liver injury
[28], and that elevated Hgf could protect hepatocytes
from injury or promote hepatocellular regeneration [29].
Since Inhba, so-called activin A, is a negative regulator of
hepatocyte cell growth [30], the decreased expression of
Inhba observed after comfrey treatment suggests the
induction of hepatic growth.
Necrosis of hepatocytes and mesenchymal cells follows
comfrey-induced liver cell injury, and functional cells are
replaced by fibrotic tissues [27,31,32]. In the present
study, we observed 16 genes involved in the function of
liver fibrosis by Ingenuity Pathway Analysis (Table 4).
Liver fibrosis is characterized by cell proliferation and the
accumulation of extracellular matrix components and is
mediated by cytokines and growth factors, of which TGF-
β1 appears to be a key mediator [32]. The up-regulation of
cytokines Hgf and Tnfrsf6 and down-regulation of Igf1
and Lif play an important role in the pathogenesis of liver
injury and fibrosis. Decreased serum Igf-1 levels provide a
useful index of hepatocellular dysfunction and impaired
nutritional status, and increased Hgf appears to limit liver
fibrosis [33]. Agt and Agtr1a, cytokines with vasoactive
properties, also regulate liver fibrogenesis. Chemokines
have a much wider biological role including angiogenesis,
carcinogenesis, and cell cycle control [34]. Chemokines in
the liver (Cxcl4 and Cxcl12) may modulate the progres-
sion of liver fibrosis through their actions on hepatic stel-
late cells.
PA-induced DNA damage in the liver (endothelial cells
and hepatocytes), if not repaired prior to DNA synthesis,
might produce replication errors and mutations, which
eventually could result in the development of neoplasmas
in the treated animals. We determined MFs in the liver cII
gene of Big Blue transgenic rats. After feeding with 8%
comfrey root for 12 weeks, we observed a 4-fold higher
MF in the liver cII gene compared to the controls (Figure
2). The induction of mutation was similar to that reported
previously for rats fed with 2% comfrey root [10]. These
observations suggest that the rats could not tolerate the
feeding of roots in concentrations over 2%, in terms of
mutation induction. Furthermore, the overall pattern of
mutations induced by 8% comfrey in liver was similar to
that in the livers of rats fed 2% comfrey root (Table 1),
whereas both the 2% and 8% comfrey-induced mutation
spectra were significantly different from liver controls. In
contrast to the G:C → A:T transition that was the predom-
inant mutation in the controls, the major type of muta-
tion in the 8% comfrey-fed rats was G:C → T:A
transversion (41%), a mutation that was also induced by
riddelliine, a representative genotoxic PA that is tumori-
genic for rat liver [35]. In addition, 13% of mutations
from the 8% comfrey-fed rats were tandem base substitu-
tion, which has been suggested as a mutational signature
for the genetic damage of PAs [36]. G:C → T:A transver-
sion may cause the initiation of tumors in the liver of rats
fed with comfrey, because it has been reported that more
than half of riddelliine-induced liver hemangiosarcomas
have a G → T mutation at K-ras codon 12 [37]. p53 muta-
tion also has been detected at an early stage of riddelliine
exposure [38]. Mutations are thought to be involved in
carcinogenesis because the transition from a normal
somatic cell to a cancer cell is due to mutations in pro-
tooncogenes, tumor suppressor genes and/or genes that
function in the maintenance of genomic stability [39,40].
Comfrey-induced neoplasms in the rat were mostly found
in the liver. Hepatocellular adenomas were induced in all
experimental groups that received diets containing 1–8%
comfrey root or 8–33% comfrey leaves. In addition, a few
rats bearing hepatocellular adenomas simultaneously had
hemangioendothelial sarcoma of the liver [9]. The first
hepatocellular carcinoma (HCC) appearance was 7
months after initiating the 8% comfrey diet.
Ingenuity Pathway Analysis found 8 genes (2 down- and
6 up -regulated) involved in liver cancer development that
were altered due to comfrey treatment (Table 5). In mam-
mals, the nucleotide excision repair process is the most
important repair pathway for elimination of DNA damage
caused by exogenous agents, including UV light, DNA-
reactive carcinogens, and some endogenously generated
oxidative lesions [41]. Xeroderma pigmentosum group C
(Xpc) is implicated in the early steps of this repair path-
way. A significantly higher incidence of chemically
induced liver and lung tumors is observed in Xpc null
mice [42]. Gap junction membrane channel protein beta
1 (Gjb1), also called connexin 32 (Cx32), is the main gap
junction protein in hepatocytes and plays an important
role in the regulation of signal transfer and growth control
in the liver. It has been reported that Cx32 expression
decreases gradually as liver disease progresses to cirrhosis
and HCC [43], and a low expression of Cx32 mRNAs in
HCC tissues is also predictive of the postoperative recur-
rence of HCCs [44]. Bcl-2 is characterized as an antiapop-
totic/oncogenic protein and also functions as an
antioxidant. Increased Bcl-2 expression in cirrhotic
patients correlates with the development of HCC [45].
Bcl-2 is also expressed in HCC tissues and the increasing
Bcl-2 expression associated with HCC progression sug-
gests that the Bcl-2 protein takes part in the formation of
HCC [46]. Hgf, identified originally as the most potent
mitogen for hepatocytes, is now known to be a cytokine
with numerous functions in a wide variety of cells [47]. It
is up-regulated in inflammatory liver diseases and stimu-
lates DNA synthesis preferentially in initiated hepato-
cytes, presumably resulting in tumour promotion [48]. N-
myc downstream-regulated gene 1 (Ndr1, or Ndrg1) plays
a role in growth arrest and cell differentiation, is inducedBMC Bioinformatics 2006, 7(Suppl 2):S16
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by several stress conditions, and is overexpressed in many
cancers [49]. Expression of Ndrg1 was significantly up-
regulated in HCC tissues compared to that of noncancer-
ous and normal liver tissues [50]. Cyclin E (Ccne1), a reg-
ulatory subunit of cyclin-dependent kinase 2, is an
important regulator for entry into the S phase of the mam-
malian cell cycle. Overexpression of Ccne1 has been
observed in many tumors including primary HCCs [51];
overexpression results in chromosome instability and
thus may contribute to tumorigenesis [52]. Growth arrest
and DNA damage 45 alpha (Gadd45a) is a nuclear pro-
tein involved in the maintenance of genomic stability,
DNA repair, and the suppression of cell growth [53].
Gadd45a protein levels are higher in liver cirrhotic and
neoplastic tissues [54]. Tissue inhibitor of metalloprotei-
nase 1 (Timp1) is a contributory factor to fibrosis of a vari-
ety of organs including the liver. Timp1 and other
extracellular matrix remodeling genes are implicated in
the transition from mild to moderate fibrosis in patients
with chronic hepatitis C [55].
Conclusion
The integration of gene expression changes with a mecha-
nistic pathway analysis suggests a scheme for comfrey
treatment leading to tumorigenesis via mutation induc-
tion (Figure 5). The available evidence suggests that active
metabolites of PAs in comfrey interact with endothelial
and hepatocyte DNA, causing damage to hepatic endothe-
lial cells and hepatocytes. This may result in liver fibrosis
and increases in mutation induction, which may be asso-
ciated with the development of HCC and hemagiosar-
coma. We have identified 2,726 genes in the livers of
comfrey-fed rats that were differentially expressed. Some
of the gene changes are associated with the metabolism,
injury of endothelial cells, and liver injury and abnormal-
ities that are postulated to occur as a result of comfrey
exposure. This approach provides further insight into the
mechanisms involved in the development of VOD/SOS
and tumorigenesis after exposure to comfrey.
Materials and methods
Plant material and animals
Comfrey roots (Symphytum officinale) were purchased
from Camas Prairie Products (Trout Lake, WA). Male Big
Blue Fisher 344 transgenic rats were obtained from
Taconic Laboratories (Germantown, NY) through pur-
chase from Stratagene (La Jolla, CA). All animal proce-
dures followed the recommendations of the NCTR
Institutional Animal Care and Use Committee for the
handling, maintenance, treatment, and sacrifice of the
rats.
Comfrey diet and treatments
The comfrey roots were ground into powder using a Wiley
Mill, and the comfrey root powder was stored at room
temperature until use. NIH-31 pellets (Purina Mills Inter-
national, Brentwood, MO) were autoclaved and ground
into meal form. The base diet was blended with comfrey
root powder in a Hobart Mixer to make 8% comfrey root
dosed diet, which was provided in rat feeders. The treat-
ment schedule was based on the protocol used in a car-
cinogenesis assay [9]. Male, 6-week-old Big Blue rats were
fed without (vehicle control group) or with 8% comfrey
roots for 12 weeks. Six rats from each treatment group
were sacrificed at the end of the treatment. The livers were
isolated, frozen quickly in liquid nitrogen, and stored at -
80°C.
cII mutation assay
High-molecular-weight genomic DNA was extracted from
rat livers using the RecoverEase DNA Isolation Kit (Strata-
gene) and stored at 4°C until DNA packaging was per-
formed. The packaging of the phage, plating the packaged
DNA samples, and determination of MF were carried out
following the manufacturer's instructions for the λ Select-
cII Mutation Detection System for Big Blue Rodents (Strat-
agene). The shuttle vector containing the cII target gene
was rescued from total genomic DNA with phage packag-
ing extract (Transpack, Stratagene). The plating was per-
formed with the Escherichia coli host strain G1250. To
determine the total titer of packaged phages, G1250 bac-
teria were mixed with 1:3000 dilutions of phage, plated
on TB1 plates, and incubated overnight at 37°C (nonse-
lective conditions). For mutant selection, the packaged
phages were mixed with G1250, plated on TB1 plates, and
incubated at 24°C for about 42 h (conditions for cII-selec-
tion). Under these conditions, phages with wild-type cII
genes undergo lysogenization and become part of the
developing bacterial lawn, whereas phages with mutated
cII genes undergo lytic growth and give rise to plaques.
When incubated at 37°C, phages with wild-type cII genes
also undergo a lytic cycle, resulting in plaque formation.
Assays were repeated until a minimum of 2 × 105 plaque-
forming units from each sample were examined for muta-
tion. The cII MF is defined as the total number of mutant
plaques (determined at 24°C) divided by the total
number of plaques screened (determined at 37°C).
Sequence analysis of the cII mutants
The mutants were sequenced according to the method of
Mei et al. [36]. The cII mutant plaques were selected at
random from different animals and replated at low den-
sity to verify the mutant phenotype. Single, well-isolated
plaques were selected from these plates and transferred to
a microcentrifuge tube containing 100 μl of sterile dis-
tilled water. The tube was heated at 100°C for 5 min and
centrifuged at 12,000 g for 3 min. The cII target DNA for
sequencing was amplified by PCR using primers 5'-
AAAAAGGGCATCAAATTAACC-3' (upstream) and 5'-
CCGAAGTTGAGTATTTTTGCTG-3' (downstream). ForBMC Bioinformatics 2006, 7(Suppl 2):S16
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Integration of gene expression with the proposed mechanistic pathway initiated by comfrey treatment leading to tumorigenesis Figure 5
Integration of gene expression with the proposed mechanistic pathway initiated by comfrey treatment leading to tumorigene-
sis. Responses in boxes represent gene expression observations and arrows in the boxes indicate direction of indicated 
response.
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PCR amplification, 10 μl of the supernatant were added to
10 μl of a PCR Master Mix (Promega, Madison, WI) and
the primers. The final concentrations of the reagents were:
1× Taq polymerase reaction buffer, 0.2 μM of each primer,
200 μM of each dNTP, 1.5 mM MgCl2, and 0.25 U of Taq
DNA polymerase. The PCR reactionwas performed using
a PCR System 9700 (Applied Biosystems, Foster City, CA),
with the following cycling parameters: a 3 min denatura-
tion at 95°C, followed by 35 cycles of 30 s at 95°C, 1 min
at 60°C, and 1 min at 72°C, with a final extension of 10
min at 72°C. The PCR products were isolated using a PCR
purification kit (Qiagen, Chatsworth, CA). The cII mutant
DNA was sequenced with a CEQ Dye Terminator Cycle
Sequencing Kit and a CEQ 8000 Genetic Analysis System
(Beckman Coulter, Fullerton, CA). The primer for cII
mutation sequencing was the upstream primer used for
the PCR.
Statistical analyses for mutagenicity data
Analyses were performed using the SigmaStat 2.03 pro-
gram (SPSS, Chicago, IL). All of the MF data were
expressed as the mean ± standard deviation (SD) from 6
rats per group. Statistical significance was determined by
one-way analysis of variance (ANOVA) followed by the
Holm-Sidak test. Mutational spectra were compared using
the computer program written by Cariello and colleagues
[56] for the Monte Carlo analysis developed by Adams
and Skopek [57].
RNA isolation and quality control
Total RNA was isolated from liver tissues of 6 control and
6 comfrey-fed rats using an RNeasy system (Qiagen). The
yield of the extracted RNA was determined spectrophoto-
metrically by measuring the optical density at 260 nm.
The purity and quality of extracted RNA were evaluated
using the RNA 6000 LabChip and Agilent 2100 Bioana-
lyzer (Agilent Technologies, Palo Alto, CA). RNA samples
with RNA integrity numbers (RINs) greater than 7.5 were
used for microarray experiments performed using Applied
Biosystems' Rat Genome Survey Microarray platform,
which is a one channel microarray with chemilumines-
cence detection, and contains 26,857 probes (60-mer) for
the interrogation of 27,088 genes and 1592 controls that
track system performance through each experiment.
Preparation of digoxigenin labeled in vitro transcribed 
cRNA
All RNA targets were labeled using the Applied Biosystems
RT-IVT Labeling Kit Version 2.0. Briefly, 1.5 μg of total
RNA was reverse transcribed via 2 h incubation at 42°C
with ArrayScript RT enzyme (Ambion, Austin, TX) and
oligo dT-T7 primer. Double stranded cDNA was produced
following 2 h incubation with E. coli DNA polymerase
and RNase H at 16°C. Double-stranded cDNA was puri-
fied according to the RT-IVT kit protocol. In vitro tran-
scription was performed by incubation of the cDNA
product with T7 RNA polymerase, 0.75 mM Digoxigenin-
11-UTP (Roche Applied Science, Indianapolis, IN) and all
other NTPs for 9 h. Labeled cRNA was purified according
to the RT-IVT kit protocol and analyzed for quality and
quantity using standard UV spectrometry and the Bioana-
lyzer.
Hybridization of labeled cRNA to microarrays and 
microarray imaging
Digoxigenin labeled cRNA targets were hybridized to
Applied Biosystems Rat Whole Genome Survey Microar-
rays using the Applied Biosystems Chemiluminescent
Detection Kit. Briefly, 15 μg of labeled cRNA targets were
fragmented via incubation with fragmentation buffer pro-
vided in the kit for 30 min at 60°C. Fragmented targets
were hybridized to microarrays during a 16 h incubation
at 55°C with buffers and reagents from the Chemilumi-
nescent Detection Kit. Post-hybridization washes and
anti-Digoxigenin-Alkaline Phosphatase binding were per-
formed according to the protocol of the kit. Chemilumi-
nescence detection, image acquisition and analysis were
performed using Applied Biosystems Chemiluminescence
Detection Kit and Applied Biosystems 1700 Chemilumi-
nescent Microarray Analyzer following the manufacturer's
protocols. Images were auto-gridded and the chemilumi-
nescent signals were quantified, corrected for background,
and finally, spot- and spatially-normalized using the
Applied Biosystems 1700 Chemiluminescent Microarray
Analyzer software version 1.1.
Microarray data analysis
Gene expression data from the Applied Biosystems' Rat
Genome Survey Microarray were input to ArrayTrack, a
software system developed by the FDA's National Center
for Toxicological Research for the management, analysis,
visualization and interpretation of microarray data [58].
Raw microarray intensity data were normalized per chip
to the same median intensity value of 500. Chemilumi-
nescent signals from 1529 control probes that track sys-
tem performance through each experiment were not used
in normalization. The identification of differentially
expressed genes based on t-tests and fold-change cutoffs,
and Principal Component Analysis were conducted
within ArrayTrack. Ingenutity Pathway Analysis (Moun-
tain View, CA) was used for pathway and function analy-
sis.
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